Stada Grabs GSK Brands In EU
German Generics Giant Becomes Major Consumer Healthcare Player
Executive Summary
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.
You may also be interested in...
Who’s Hired? Stada Makes Moves In Germany And Poland
Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.
Stada Will Continue To Invest To Drive Growth
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.